<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Valsartan: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Valsartan: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Valsartan: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11137" href="/d/html/11137.html" rel="external">see "Valsartan: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13078" href="/d/html/13078.html" rel="external">see "Valsartan: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5708863"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Fetal toxicity:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. When pregnancy is detected, discontinue valsartan as soon as possible.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F233186"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Diovan</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52868565"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Auro-Valsartan;</li>
<li>Diovan;</li>
<li>M-Valsartan;</li>
<li>SANDOZ Valsartan;</li>
<li>TARO-Valsartan;</li>
<li>TEVA-Valsartan</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F233224"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Angiotensin II Receptor Blocker;</li>
<li>
                        Antihypertensive</li></ul></div>
<div class="block doa drugH1Div" id="F233191"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information:</b> The commercially available oral solution and extemporaneously compounded oral suspension have greater bioavailability than tablets. All doses shown in this monograph are for the oral tablets. When converting to an oral liquid preparation, reassess dose.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8c422ce2-49d1-404f-9c62-15c216a263dd">Acute coronary syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute coronary syndrome:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Alternative in patients who cannot tolerate an angiotensin-converting enzyme (ACE) inhibitor (eg, due to cough) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25260718','lexi-content-ref-23247304','lexi-content-ref-Guyer.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25260718','lexi-content-ref-23247304','lexi-content-ref-Guyer.1'])">Ref</a></span>). In patients with prior ACE inhibitor–associated angioedema (ie, without urticaria or other signs of hypersensitivity), an angiotensin II receptor blocker (ARB) may still be an alternative. ARBs do not appear to elevate the risk of angioedema (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30618189','lexi-content-ref-23147456']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30618189','lexi-content-ref-23147456'])">Ref</a></span>); however, patients must be educated that angioedema due to an ACE inhibitor can sometimes reoccur within months following discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21970934']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21970934'])">Ref</a></span>); referral to an allergist may be appropriate.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Non–ST-elevation acute coronary syndrome (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Initiate in stable patients prior to hospital discharge as a component of an appropriate medical regimen, which may include antiplatelet agent(s), a beta-blocker, and a statin. Continue indefinitely for patients with concurrent diabetes, left ventricular ejection fraction ≤40%, hypertension, or stable chronic kidney disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25260718']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25260718'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Initial: 20 mg twice daily; may increase dose as tolerated up to 160 mg twice daily under close monitoring to avoid hypotension.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>ST-elevation myocardial infarction (alternative agent):</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> In hemodynamically stable patients with large anterior ST-elevation myocardial infarction, consider starting within 24 hours of presentation as a component of an appropriate medical regimen, which may include antiplatelet agent(s), a beta-blocker, and a statin. Continue therapy indefinitely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23247304']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23247304'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Initial: 20 mg twice daily; may increase dose as tolerated up to 160 mg twice daily under close monitoring to avoid hypotension. <b></b></p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b43376ec-cceb-40f9-ad1e-9137f312af09">Heart failure with reduced ejection fraction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heart failure with reduced ejection fraction (alternative agent):</b>
<b></b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Alternative therapy in patients who cannot tolerate an angiotensin II receptor-neprilysin inhibitor (ARNI) or an ACE inhibitor (eg, due to cough or angioedema); consultation with a heart failure specialist and/or an allergist may be appropriate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499','lexi-content-ref-Guyer.1','lexi-content-ref-Meyer.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499','lexi-content-ref-Guyer.1','lexi-content-ref-Meyer.2020'])">Ref</a></span>). ARBs do not appear to elevate the risk of angioedema (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30618189','lexi-content-ref-23147456']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30618189','lexi-content-ref-23147456'])">Ref</a></span>); however, angioedema due to an ACE inhibitor can sometimes reoccur within months following discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21970934']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21970934'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 20 to 40 mg twice daily; increase dose (eg, double) every ≥1 to 2 weeks based on response and tolerability to a target dose of 160 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499'])">Ref</a></span>). In hospitalized patients, may titrate more rapidly as tolerated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Meyer.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Meyer.2020'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4f0c92d9-ad08-4643-a848-3296ddf5258e">Hypertension, chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension, chronic: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For patients who warrant combination therapy (BP &gt;20/10 mm Hg above goal or suboptimal response to initial monotherapy), may use with another appropriate agent (eg, long-acting dihydropyridine calcium channel blocker or thiazide diuretic) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 80 to 160 mg once daily; evaluate response after ~2 to 4 weeks and titrate dose (eg, increase the daily dose by doubling) as needed up to a maximum of 320 mg once daily; if additional blood pressure control is needed, consider combination therapy. Patients with severe asymptomatic hypertension and no signs of acute end organ damage should be evaluated for medication titration within 1 week (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29133356','lexi-content-ref-Mann.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29133356','lexi-content-ref-Mann.1'])">Ref</a></span>). If the commercially available oral solution is used, the manufacturer labeling recommends administering the dose in 2 divided doses.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2d8b6822-d348-4d03-bd66-4ea05b5dd0a9">Proteinuric chronic kidney disease, diabetic or nondiabetic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Proteinuric chronic kidney disease, diabetic or nondiabetic (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 80 to 160 mg once daily or in two divided doses depending on baseline BP; titrate gradually (eg, by doubling the dose every 2 to 4 weeks) up to the maximally tolerated dose, not to exceed 320 mg/day. If proteinuria target is not met despite optimized dosage, consider additional therapies (eg, sodium-glucose cotransporter-2 inhibitor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Cattran.1','lexi-content-ref-34556256','lexi-content-ref-36272764','lexi-content-ref-16632013','lexi-content-ref-Perkovic.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Cattran.1','lexi-content-ref-34556256','lexi-content-ref-36272764','lexi-content-ref-16632013','lexi-content-ref-Perkovic.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991252"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> No dosage adjustment necessary for any degree of kidney dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Prasad.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Prasad.1'])">Ref</a></span>). <b>Note:</b> Use with caution in patients with kidney impairment (especially CrCl &lt;30 mL/minute); monitor kidney function and potassium more closely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not significantly dialyzed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>): No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be dialyzed (highly protein bound): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988507"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Should be used with caution in patients with ascites due to cirrhosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33942342','lexi-content-ref-23463403']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33942342','lexi-content-ref-23463403'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment: No initial dosage adjustment necessary; use with caution.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment: There are no dosage adjustments provided in the manufacturer's labeling; use with caution.</p></div>
<div class="block doe drugH1Div" id="F233192"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F5605992"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13078" href="/d/html/13078.html" rel="external">see "Valsartan: Pediatric drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bc4b3de7-1b7f-4f34-9c5e-fb2c0aab85f9">Hypertension</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Oral dosage forms (tablets and compounded suspension) are not bioequivalent on a mg:mg basis. Due to increased bioavailability of extemporaneously prepared oral suspension, patients may require a higher dose when converting from oral suspension to tablet dosage form. Extemporaneously compounded oral suspension is recommended for patients ≤5 years of age and patients &gt;5 years of age who are either unable to swallow tablets whole or their calculated dose (mg/kg) does not correspond to an available tablet strength (see "Extemporaneous Preparations").</p>
<p style="text-indent:-2em;margin-left:6em;">Consider lower listed initial dose in patients with hyponatremia, hypovolemia, severe congestive heart failure, decreased renal function, or in those receiving diuretics.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants ≥6 months and weighing ≥6 kg: Limited data available; optimal dosage not defined: Oral: Extemporaneously compounded oral suspension was used in the trial: Initial: 1 mg/kg/dose once daily; titrate every 2 weeks to effect up to a maximum daily dose: 4 mg/kg/<b>day</b>; reported dosage range: 0.25 to 4 mg/kg/dose once daily; maximum daily dose: 4 mg/kg/<b>day </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23511339']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23511339'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents &lt;17 years: Oral: Initial: 1 mg/kg/dose once daily; maximum initial daily dose: 40 mg/<b>day</b>; some patients may require a higher initial dose of 2 mg/kg/dose once daily. May titrate to effect up to a maximum daily dose: 4 mg/kg/<b>day</b> not to exceed 160 mg/<b>day</b>. <b>Note:</b> Obese pediatric patients 6 to 16 years were observed to respond at similar doses as nonobese (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21974764']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21974764'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents ≥17 years: Oral: Initial: 80 mg or 160 mg once daily; some patients may require a higher initial dose. May titrate to effect up to a maximum daily dose: 320 mg/<b>day</b>.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51193230"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children and Adolescents: Hypertensive pediatric patients may have associated renal abnormalities; monitor SCr and potassium closely in these patients; SCr may increase when initiating therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl ≥30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">CrCl &lt;30 mL/minute/1.73 m<sup>2</sup>: There are no dosage adjustments provided in the manufacturer's labeling; has not been studied; use with caution; valsartan use in chronic kidney disease undefined (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30177515','lexi-content-ref-25018935']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30177515','lexi-content-ref-25018935'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">Dialysis: Not significantly removed.</p></div>
<div class="block dohp drugH1Div" id="F51193231"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate impairment: No initial dosage adjustment necessary; use caution in patients with liver disease. Patients with mild to moderate chronic disease have twice the exposure as healthy volunteers.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: There are no dosage adjustments provided in manufacturer's labeling; has not been studied; use with caution.</p></div>
<div class="block arsc drugH1Div" id="F56796788"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Acute kidney injury</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Valsartan may be associated with <b>increased serum creatinine </b>and/or<b> acute kidney injury</b>. Increases in serum creatinine secondary to angiotensin receptor blockers usually stabilize within 20% to 30% from baseline and are expected; additional increases may indicate renal artery stenosis or volume depletion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25018935','lexi-content-ref-11602506','lexi-content-ref-10619572']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25018935','lexi-content-ref-11602506','lexi-content-ref-10619572'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Related to pharmacologic action; inhibits efferent renal arteriolar vasoconstriction, lowering glomerular filtration pressure which can lead to a modest reduction in glomerular filtration rate (GFR) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10619572']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10619572'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Expected to be similar to angiotensin-converting enzyme inhibitors: Intermediate; transient increases in serum creatinine generally occur within 2 weeks initiation and stabilize within 2 to 4 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10724055']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10724055'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Sodium or volume depletion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23176216','lexi-content-ref-18695383','lexi-content-ref-10619572']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23176216','lexi-content-ref-18695383','lexi-content-ref-10619572'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Heart failure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18695383']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18695383'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent diuretic and/or nonsteroidal anti-inflammatory use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23176216','lexi-content-ref-18695383','lexi-content-ref-10619572']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23176216','lexi-content-ref-18695383','lexi-content-ref-10619572'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients</p>
<p style="text-indent:-2em;margin-left:6em;">• Hypotension (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23176216','lexi-content-ref-18695383']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23176216','lexi-content-ref-18695383'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Preexisting kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23176216','lexi-content-ref-18695383','lexi-content-ref-10619572']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23176216','lexi-content-ref-18695383','lexi-content-ref-10619572'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with low renal blood flow (eg, renal artery stenosis) whose GFR is dependent on efferent arteriolar vasoconstriction by angiotensin II (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23176216','lexi-content-ref-18695383','lexi-content-ref-10619572']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23176216','lexi-content-ref-18695383','lexi-content-ref-10619572'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hyperkalemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperkalemia </b>may occur in adult and pediatric patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22025233']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22025233'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism: </i>Related to the pharmacologic action; blocks angiotensin II from binding to the adrenal receptor and interferes with generation of angiotensin II within the adrenal cortex, decreasing aldosterone release and impairing renal potassium excretion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1855477','lexi-content-ref-21883995']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1855477','lexi-content-ref-21883995'])">Ref</a></span>).</p>
<p style="text-indent:0em;margin-left:2em;">
<i>Onset:</i> Generally occurs within 1 week of treatment initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24262001']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24262001'])">Ref</a></span>).</p>
<p style="text-indent:0em;margin-left:2em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• High dietary intake of potassium (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17996561','lexi-content-ref-15295051']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17996561','lexi-content-ref-15295051'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Baseline elevated potassium (≥5 mmol/L) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17996561','lexi-content-ref-15295051']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17996561','lexi-content-ref-15295051'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17996561','lexi-content-ref-15295051']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17996561','lexi-content-ref-15295051'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Kidney dysfunction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17996561','lexi-content-ref-15295051']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17996561','lexi-content-ref-15295051'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Diabetes mellitus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17996561','lexi-content-ref-15295051']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17996561','lexi-content-ref-15295051'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of medications known to decrease renin and aldosterone (eg, direct renin inhibitors, nonsteroidal anti-inflammatory drugs, cyclosporine, tacrolimus, beta-blockers, sulfamethoxazole/trimethoprim, azole antifungals) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20585070','lexi-content-ref-15295051']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20585070','lexi-content-ref-15295051'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salt substitutes (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17996561','lexi-content-ref-15295051']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17996561','lexi-content-ref-15295051'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F233152"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults. Adverse reactions occurred with heart failure or post-MI unless otherwise indicated.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (17%; hypertension: 2% to 8%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased blood urea nitrogen (&gt;50% increase: 17%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Hypotension (6% to 7%; hypertension: &lt;1%), orthostatic dizziness (2%), orthostatic hypotension (2%), syncope (&gt;1%; hypertension: &lt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hyperkalemia (2%)<span class="lexi-table-link-container"> (<a aria-label="Hyperkalemia table link" class="lexi-table-link" data-table-id="lexi-content-hyperkalemia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hyperkalemia')">table 1</a>)</span><span class="table-link" style="display:none;">Hyperkalemia</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hyperkalemia" frame="border" id="lexi-content-hyperkalemia" rules="all">
<caption style="text-align:center;">
<b>Valsartan: Adverse Reaction: Hyperkalemia</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Valsartan)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Valsartan)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Heart failure</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3,282</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,740</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (hypertension: 2%), diarrhea (5%), nausea (&gt;1%), upper abdominal pain (&gt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Neutropenia (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (3%; hypertension: 2%), headache (&gt;1%), vertigo (&gt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (3%), back pain (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (&gt;1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (4%)<span class="lexi-table-link-container"> (<a aria-label="Increased Serum Creatinine table link" class="lexi-table-link" data-table-id="lexi-content-increased-serum-creatinine" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-increased-serum-creatinine')">table 2</a>)</span><span class="table-link" style="display:none;">Increased Serum Creatinine</span>, renal insufficiency (&gt;1%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Increased Serum Creatinine" frame="border" id="lexi-content-increased-serum-creatinine" rules="all">
<caption style="text-align:center;">
<b>Valsartan: Adverse Reaction: Increased Serum Creatinine</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Valsartan)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Captopril)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Valsartan)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Captopril)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Comments</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0.9%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Heart failure</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3,282</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2,740</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">&gt;50% Increase in creatinine</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Post-myocardial infarction</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4,885</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">4,879</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Doubling of creatinine</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dry cough (hypertension: 3%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Vasculitis</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, bullous dermatitis (Gao 2021), lichenoid eruption (Gencoglan 2009), skin rash (Ozturk 2012)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis, increased liver enzymes</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema (Alhowary 2018, Kalra 2012)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Rhabdomyolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury</p></div>
<div class="block coi drugH1Div" id="F233166"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to valsartan or any component of the formulation; concomitant use with aliskiren in patients with diabetes mellitus.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Concomitant use with aliskiren in patients with moderate to severe kidney impairment (GFR &lt;60 mL/minute/1.73 m<sup>2</sup>); pregnancy; breastfeeding.</p></div>
<div class="block war drugH1Div" id="F233149"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Angioedema: Angiotensin II receptor antagonists (ARBs) do not appear to elevate the risk of angioedema (Rasmussen 2019; Toh 2012). Patients with a history of angioedema due to an angiotensin-converting enzyme inhibitor must be educated that sometimes there can be recurrence within months following discontinuation (Beltrami 2011). No matter the cause of angioedema, prolonged frequent monitoring is required, especially if tongue, glottis, or larynx are involved, as they are associated with airway obstruction. Discontinue therapy immediately if angioedema occurs. Aggressive early management is critical. IM administration of epinephrine may be necessary. Do not readminister the ARB to patients who experience angioedema from this medication.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypotension: Symptomatic hypotension may occur upon initiation in patients who are salt- or volume-depleted (eg, those treated with high-dose diuretics); correct volume depletion prior to administration. This transient hypotensive response is not a contraindication to further treatment with valsartan.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Aortic/mitral stenosis: Use with caution in patients with significant aortic/mitral stenosis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Ascites: Generally, avoid use in patients with ascites due to cirrhosis or refractory ascites; if use cannot be avoided in patients with ascites due to cirrhosis, monitor BP and kidney function carefully to avoid rapid development of kidney failure (AASLD [Runyon 2013]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment (exposure to valsartan is increased).</p>
<p style="text-indent:-2em;margin-left:4em;">• Kidney impairment: Use with caution in patients with kidney impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Race/Ethnicity: In Black patients, the BP-lowering effects of ARBs may be less pronounced. The exact mechanism is not known; differences in the renin-angiotensin-aldosterone system, low renin levels, and salt sensitivity more commonly found in Black patients may contribute (Brewster 2013; Helmer 2018; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">• Surgical patients: In patients on chronic ARB therapy, intraoperative hypotension may occur with induction and maintenance of general anesthesia; however, discontinuation of therapy prior to surgery is controversial. If continued preoperatively, avoidance of hypotensive agents during surgery is prudent (ACCF/AHA [Hillis 2011]). Based on current research and clinical guidelines in patients undergoing noncardiac surgery, continuing ARBs is reasonable in the perioperative period. If ARBs are held before surgery, it is reasonable to restart postoperatively as soon as clinically feasible (ACC/AHA [Fleisher 2014]).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Product interchangeability: The commercially available oral solution, extemporaneously compounded oral suspension, and tablets are not interchangeable with each other due to differences in pharmacokinetics; do not combine the 2 dosage forms to achieve the total dose.</p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated with hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007).</p></div>
<div class="block foc drugH1Div" id="F233160"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 4 mg/mL (120 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Diovan: 40 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Diovan: 80 mg, 160 mg, 320 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 40 mg, 80 mg, 160 mg, 320 mg</p></div>
<div class="block geq drugH1Div" id="F233145"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F233169"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Valsartan Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg/mL (per mL): $2.75 - $9.27</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Diovan Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $9.28</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 mg (per each): $11.09</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">160 mg (per each): $11.93</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">320 mg (per each): $15.09</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Valsartan Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $0.25 - $5.12</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">80 mg (per each): $0.29 - $6.12</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">160 mg (per each): $0.31 - $6.58</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">320 mg (per each): $0.37 - $8.32</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52868566"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Diovan: 40 mg, 80 mg, 160 mg, 320 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 40 mg, 80 mg, 160 mg, 320 mg</p></div>
<div class="block adm drugH1Div" id="F233163"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Oral solution: Administer consistently with regard to food because high-fat meals decrease AUC ~8% and C<sub>max</sub> ~44%.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral suspension: Shake well before use.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablets: Administer with or without food.</p></div>
<div class="block admp drugH1Div" id="F52613997"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May be administered without regard to food; shake oral suspension well before use.</p>
<p style="text-indent:-2em;margin-left:2em;">Missed dose: Take missed dose as soon as possible unless almost time for the next dose; do not double a dose to make up for a missed dose.</p></div>
<div class="block use drugH1Div" id="F233161"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Heart failure with reduced ejection fraction: </b>Treatment of heart failure (NYHA class II to IV) in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertension, chronic:</b> Management of hypertension in adults and pediatric patients ≥1 year of age (tablet) or ≥6 years of age (oral solution).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Post–myocardial infarction:</b> Reduction of cardiovascular mortality in patients with left ventricular dysfunction or failure following myocardial infarction (MI) (eg, acute coronary syndromes such as ST-elevation MI or non–ST-elevation MI) in adults.</p></div>
<div class="block off-label drugH1Div" id="F48838296"><span class="drugH1">Use: Off-Label: Adult</span><p>Proteinuric chronic kidney disease, diabetic or nondiabetic</p></div>
<div class="block mst drugH1Div" id="F233232"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Valsartan may be confused with losartan, Valstar, Valturna</p>
<p style="text-indent:-2em;margin-left:4em;">Diovan may be confused with Zyban</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Diovan [US, Canada, and multiple international markets] may be confused with Dianben, a brand name for metformin [Spain]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F233218"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of MRP2, OATP1B1/1B3 (SLCO1B1/1B3)</p></div>
<div class="block dri drugH1Div" id="F233154"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aliskiren: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the hypotensive effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the nephrotoxic effect of Angiotensin II Receptor Blockers. Management: Aliskiren use with ACEIs or ARBs in patients with diabetes is contraindicated. Combined use in other patients should be avoided, particularly when CrCl is less than 60 mL/min. If combined, monitor potassium, creatinine, and blood pressure closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When used at chemotherapy doses, hold blood pressure lowering medications for 24 hours before amifostine administration. If blood pressure lowering therapy cannot be held, do not administer amifostine. Use caution with radiotherapy doses of amifostine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin II: Receptor Blockers may diminish the therapeutic effect of Angiotensin II.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Angiotensin-Converting Enzyme Inhibitors: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Angiotensin-Converting Enzyme Inhibitors. Angiotensin II Receptor Blockers may increase the serum concentration of Angiotensin-Converting Enzyme Inhibitors.  Management: Use of telmisartan and ramipril is not recommended. It is not clear if any other combination of an ACE inhibitor and an ARB would be any safer. Consider alternatives when possible. Monitor blood pressure, renal function, and potassium if combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antihepaciviral Combination Products: May increase the serum concentration of Valsartan. Management: Consider decreasing the valsartan dose and monitoring for evidence of hypotension and worsening renal function if these agents are used in combination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Arginine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asciminib: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brigatinib: May diminish the antihypertensive effect of Antihypertensive Agents. Brigatinib may enhance the bradycardic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromperidol: May diminish the hypotensive effect of Blood Pressure Lowering Agents. Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapoxetine: May enhance the orthostatic hypotensive effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Darolutamide: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate: May diminish the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Drospirenone-Containing Products: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eltrombopag: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Encorafenib: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eplerenone: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Finerenone: Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of Finerenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flunarizine: May enhance the therapeutic effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gemfibrozil: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparin: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparins (Low Molecular Weight): May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Increasing Effects: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Blood Pressure Lowering Effects: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indoramin: May enhance the hypotensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leflunomide: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Leniolisib: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levodopa-Foslevodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa-Foslevodopa. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lithium: Angiotensin II Receptor Blockers may increase the serum concentration of Lithium.  Management: Initiate lithium at lower doses in patients receiving an angiotensin II receptor blocker (ARB). Consider lithium dose reductions in patients stable on lithium therapy who are initiating an ARB. Monitor lithium concentrations closely when combined.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May enhance the hypotensive effect of Angiotensin II Receptor Blockers. Loop Diuretics may enhance the nephrotoxic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylphenidate: May diminish the antihypertensive effect of Antihypertensive Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May diminish the therapeutic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: Angiotensin II Receptor Blockers may enhance the nephrotoxic effect of Polyethylene Glycol-Electrolyte Solution. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium Salts: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Potassium-Sparing Diuretics: Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of Potassium-Sparing Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prazosin: Antihypertensive Agents may enhance the hypotensive effect of Prazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pretomanid: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ranolazine: May enhance the adverse/toxic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Silodosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium Phosphates: Angiotensin II Receptor Blockers may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: May enhance the adverse/toxic effect of Angiotensin II Receptor Blockers.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Terazosin: Antihypertensive Agents may enhance the hypotensive effect of Terazosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Teriflunomide: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolvaptan: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimethoprim: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trofinetide: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors). Management: Avoid concurrent use with OATP1B1/1B3 substrates for which small changes in exposure may be associated with serious toxicities. Monitor for evidence of an altered response to any OATP1B1/1B3 substrate if used together with trofinetide.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urapidil: Antihypertensive Agents may enhance the hypotensive effect of Urapidil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voclosporin: May increase the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Substrates (Clinically Relevant with Inhibitors).<i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F233182"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Food decreases tablet C<sub>max</sub> and AUC by 50% and 40%, respectively. Oral solution C<sub>max</sub> and AUC are decreased by ~44% and 8%, respectively, with a high-fat, high-calorie meal. Management: Administer consistently with regard to food.</p></div>
<div class="block rep_considerations drugH1Div" id="F53336899"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Avoid use of an angiotensin II receptor blocker (ARB) in patients who may become pregnant and who are not using effective contraception (ADA 2021).</p>
<p style="text-indent:0em;">Medications considered acceptable for the treatment of chronic hypertension during pregnancy may generally be used in patients trying to conceive. ARBs are fetotoxic. Transition patients prior to conception to an agent preferred for use during pregnancy (ACC/AHA [Whelton 2018]; ACOG 2019; NICE 2019).</p>
<p style="text-indent:0em;">When an ARB is used for the treatment of proteinuric chronic kidney disease in patients who could become pregnant, discontinue use at the first positive pregnancy test (ADA 2021; Fakhouri 2022).</p>
<p style="text-indent:0em;">ARBs are not recommended for the treatment of heart failure in patients planning to become pregnant (AHA/ACC/HFSA [Heidenreich 2022]).</p></div>
<div class="block pri drugH1Div" id="F233170"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Exposure to an angiotensin II receptor blocker (ARB) during the first trimester of pregnancy may be associated with an increased risk of fetal malformations (ACOG 2019; ESC [Regitz-Zagrosek 2018]). Following exposure during the second or third trimesters, drugs that act on the renin-angiotensin system are associated with oligohydramnios. Oligohydramnios, due to decreased fetal kidney function, may lead to fetal lung hypoplasia and skeletal malformations. Oligohydramnios may not appear until after an irreversible fetal injury has occurred. ARB use during pregnancy is also associated with anuria, hypotension, kidney failure, skull hypoplasia, and death in the fetus/neonate. Monitor infants exposed to an ARB in utero for hyperkalemia, hypotension, and oliguria. Exchange transfusions or dialysis may be required to reverse hypotension or improve renal function.</p>
<p style="text-indent:0em;margin-top:2em;">Chronic maternal hypertension is also associated with adverse events in the fetus/infant. Chronic maternal hypertension may increase the risk of birth defects, low birth weight, preterm delivery, stillbirth, and neonatal death. Actual fetal/neonatal risks may be related to the duration and severity of maternal hypertension. Untreated hypertension may also increase the risk of adverse maternal outcomes, including gestational diabetes, myocardial infarction, preeclampsia, stroke, and delivery complications (ACOG 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Discontinue ARBs as soon as possible once pregnancy is detected. Agents other than an ARB are recommended for the treatment of chronic hypertension during pregnancy (ACOG 2019; ESC [Cífková 2020]; ESC [Regitz-Zagrosek 2018]; SOGC [Magee 2022]). Closely monitor patients exposed to an ARB during pregnancy with serial ultrasounds.</p>
<p style="text-indent:0em;margin-top:2em;">ARBs are not recommended for the treatment of heart failure or proteinuric chronic kidney disease during pregnancy (AHA/ACC/HFSA [Heidenreich 2022]; ESC [Regitz-Zagrosek 2018]; Fakhouri 2022).</p></div>
<div class="block brc drugH1Div" id="F5631008"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if valsartan is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer. When treatment for hypertension is needed in a breastfeeding patient, consider use of an agent other than an angiotensin II receptor blocker (ESC [Cífková 2020]; NICE 2019).</p></div>
<div class="block dic drugH1Div" id="F233171"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Avoid salt substitutes which contain potassium.</p></div>
<div class="block mop drugH1Div" id="F233158"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Blood pressure; serum electrolytes (eg, potassium [especially in patients on concomitant potassium-sparing diuretics, potassium supplements and/or potassium containing salts]); kidney function.</p></div>
<div class="block pha drugH1Div" id="F233148"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Valsartan produces direct antagonism of the angiotensin II (AT2) receptors, unlike the ACE inhibitors. It displaces angiotensin II from the AT1 receptor and produces its blood pressure-lowering effects by antagonizing AT1-induced vasoconstriction, aldosterone release, catecholamine release, arginine vasopressin release, water intake, and hypertrophic responses. This action results in more efficient blockade of the cardiovascular effects of angiotensin II and fewer side effects than the ACE inhibitors.</p></div>
<div class="block phk drugH1Div" id="F233165"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Commercially available oral solution and extemporaneously compounded oral suspension are not therapeutically equivalent to the tablet formulation. For an equivalent dose, valsartan oral solution has 86% higher C<sub>max</sub> and 25% higher AUC compared to tablet formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: ~2 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: 24 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 17 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 95%, primarily albumin.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: To inactive metabolite (valeryl 4-hydroxy valsartan).</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Tablet: 25% (range: 10% to 35%); Suspension (extemporaneously prepared): ~40% (~1.6 times more than tablet).</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Children 1 to 5 years: ~4 hours (Blumer 2009).</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents 6 to 16 years: ~5 hours (Blumer 2009).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: ~6 hours; ~35% longer in elderly patients.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum:</p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents 1 to 16 years: Oral suspension: 2 hours (Blumer 2009).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Oral solution: 0.7 to 3.7 hours (high-fat, high-calorie meal decreased C<sub>max</sub> ~44%); Tablet: 2 to 4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Feces (83%) and urine (~13%) as unchanged drug.</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: Found to be similar per kg bodyweight in children vs adults receiving a single dose of the suspension (Blumer 2009).</p></div>
<div class="block phksp drugH1Div" id="F51204420"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Patients with mild-to-moderate chronic liver disease have about twice the AUC value.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: AUC is about 70% higher and the half-life is 35% longer in elderly patients.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F2869414"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Angiovan | Arbaval | Diovan | Extenz | Joltan | Lova | Starval | Tabuvan | Valzar | Vanguard</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Alpertan | Corosan | Diapresan | Dilcoran | Diovan | Diovan IC | Hiperval | Medicoran | Nicorvas | Paliax | Racorval | Redutensil | Sarval | Semanar | Simultan | Valsalep | Valsarfec | Valsartan northia | Valsartan teva | Vartaz</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Diovan | Valsacor | Valsartan +pharma | Valsartan 1A pharma | Valsartan actavis | Valsartan g.l. | Valsartan Genericon | Valsartan ratiopharm | Valsartan sandoz | Valsartan stada | Valsax</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo valsartan | Dilart | Diovan</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Arovan | Cardival | Cardovan | Diovan | Disys | Reovan | Valcap | Valosan | Valpress | Valsan | Valset</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Diovane | Valsamat | Valsamylan | Valsartan Apotex | Valsartan krka | Valsartan mylan | Valsartan Ranbaxy | Valsartan sandoz | Valsartan teva | Valsavil</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Starval | Valsar | Valsar denk | Valsartan win</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Diovan | Nortivan | Nortivan neo | Sarteg | Sartoval | Suvartar | Valsacor | Valsalen | Valsarcon | Valsargamma | Valsavil | Valstor | Valtensin | Valzap | Vanatex | Vapress | Walzera</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Angio II | Arterox | Aval | Brasart | Brator | Bravan | Cosartan | Diovan | Neosartan | Rovelan | Tamcore | Tareg | Valsacor | Valsartana | Valsartana eurofarma</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Diovan | Provas | Valsartan actavis | Valsartan axapharm | Valsartan Helvepharm | Valsartan sandoz | Valsartan Spirig | Valsartan Streuli | Valsartan zentiva | Valtan</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Arbiten | Dopcor | Valex | Valmac | Valsar</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Dosara | Karga | Tamcore | Tareg | Valacor | Valaplex | Valax | Valkem | Valvitae | Vartalan | Veralpres</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Dai wen | Diovan | Jia fei | Lizhu weike | Mai xin | Sui yue | Ti tan wen | Tuo ping | Xie ke | Yi fang</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Bratenzil | Cardik | Cardiotan | Clembroxol | Diovan | Presval | Racorval | Salvara | Valsad | Valsaprex | Valsarvitae | Valtan | Valutol | Varcor | Vartaz | Vasoflex</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Apo valsartan | Blessin | Diovan | Kylotan | Kylotan neo | Valsacor | Valsartan +pharma | Valsartan teva | Valzap | Vanatex | Vapress</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Cordinate | Diovan | Diovan emra med | Diovan protect | Diovane | Provas | Valsacor | Valsaraxiro | Valsargamma | Valsartan 1A pharma | Valsartan aaa | Valsartan actavis | Valsartan AL | Valsartan aurobindo | Valsartan Basics | Valsartan beta | Valsartan Biomo | Valsartan CT | Valsartan denk | Valsartan Dexcel | Valsartan Dura | Valsartan Hennig | Valsartan Heumann | Valsartan Hexal | Valsartan Hormosan | Valsartan Macleods | Valsartan puren | Valsartan Q | Valsartan ratiopharm | Valsartan stada | Valsartan zentiva</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Diovan</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Acrovan | Alsartan | Atdos | Balsartec | Diovan | Gioten | Lodelip | Lysamol | Pexabrel | Terapres | Valchem | Valdiber | Valsacor | Valsar | Valsartan Genfar | Valsartan if | Valsartan Lam | Valsartan MK | Valsartan sued | Valsartec | Valscard | Valtan | Vartalan</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Atennor | Cardik | Cardik 320 | Diovan | Hiperval | Inixia c | Pertena | Simultan | Valaplex | Valopral | Valsapress | Valsartan La Sante | Valsartan MK | Vartalan | Vartaz</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Diovan | Suvartar | Valsacor | Valsartan Medochemie | Valzap</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Adwivalsar | Cardovaldon | Disartan | Idisartan | Lasaromep | Pressval | Sordevan | Tareg | Valsarcard</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Aralter | Diovan | Kalpress | Miten | Vals | Valsacor | Valsartan actavis | Valsartan almus | Valsartan alter | Valsartan Apotex | Valsartan aurobindo | Valsartan Cantabria | Valsartan cinfa | Valsartan combix | Valsartan Davur | Valsartan kern pharma | Valsartan krka | Valsartan Mabo | Valsartan Macleods | Valsartan mundogen | Valsartan mylan | Valsartan normon | Valsartan Pensa | Valsartan pharmagenus | Valsartan qualigen | Valsartan Ranbaxy | Valsartan ratiopharm | Valsartan sandoz | Valsartan stada | Valsartan tad | Valsartan Tarbis | Valsartan tecnigen | Valsartan teva | Valsartan zentiva</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Anginet | Diovan | Tabuvan | Valazyd | Valsartan denk | Valsartan jubilant</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Diovan | Valsarstad | Valsartan actavis | Valsartan krka | Valsartan orion | Valsartan ratiopharm | Valsartan sandoz</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Diovan | Nisis | Tareg | Valsartan actavis | Valsartan ahcl | Valsartan alter | Valsartan Arrow | Valsartan biogaran | Valsartan Cristers | Valsartan EG | Valsartan evolugen | Valsartan isomed | Valsartan krka | Valsartan mylan | Valsartan Ranbaxy | Valsartan sandoz | Valsartan zentiva | Valsartan zydus</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Diovan</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Avalsan | Dalzad | Diosartan | Diovan | Valperol | Valpressol | Valsaben | Valsareta | Valsart | Valsartan teva | Valsartan/Actavis | Valsartan/generics | Valsartan/krka | Valsartan/sandoz | Valsartan/Tad | Valsartan/teva | Vamadrid | Vartisan | Velsa | Zakodian</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo valsartan | Diovan | Disys | Selectan | Syn valsartan | Valtensin</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Desart | Diovan | Val | Valnorm | Valsacor | Walzera</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Alvastran | Diovan | Nortivan | Tensart | Valsagamma | Valsarep | Valsartan krka | Valsartan sandoz | Valsartan teva | Valsocard | Valsotens | Varexan | Vezuran</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Diovan | Pavartan | Valsartan NI | Valtensi | Varten</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Diovan | Valsartan krka | Valsartan rowa | Valtan | Vatan</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Diovan | Vector</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Diovan | Starval | Valembic | Valent | Valfect | Valzaar</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Diosartan | Valsartan awa</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Alsartir | Biorax | Kerval | Pressloval | Revalsan | Rixil | Sartarex | Saval | Tareg | Valpression | Valprex | Valsacor | Valsartan actavis | Valsartan almus | Valsartan alter | Valsartan Awp | Valsartan doc generici | Valsartan dr. Reddy's | Valsartan EG | Valsartan germed | Valsartan Macleods | Valsartan mylan | Valsartan Pensa | Valsartan provvisoria | Valsartan Ranbaxy | Valsartan sandoz | Valsartan tecnigen | Valsartan zentiva | Valsoten</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Anginet | Arbiten | Diostar | Diotens | Diovan | Tabuvan | Valentine | Vapress | Vilasar</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Diovan | Valsartan "Nichi Iko" | Valsartan amel | Valsartan bmd | Valsartan chemiphar | Valsartan ee | Valsartan ffp | Valsartan isei | Valsartan jg | Valsartan kaken | Valsartan kn | Valsartan kog | Valsartan kyorin | Valsartan me | Valsartan meiji | Valsartan nipro | Valsartan nissin | Valsartan ohara | Valsartan tck | Valsartan teva | Valsartan towa | Valsartan tsuruhara | Valsartan yd | Valsartan zensei</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Diovan | Starval | Troval | Valazyd | Valsar denk | Valtero</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Auskovan | Binex valsartan | C rtan | Cirtan | Clovan | Detension | Dio v | Diopass | Diortan | Diorvan | Diosartan | Diotan | Diotech | Dioten | Diovaltan | Diovan | Diozartan | Diqvan | Dirotan | Dirtan | Disar | Divaltan | Dizantan | Dizantin | Dongkoo valsartan | Dsvan | Esaltan | Exvan | Hydn | Hyundai valsartan | Ilyangbio valsartan | Kovaltan | Maxdio | New valsartavan | Newsartan | Newvaltan | Sadivan | Samsung valsartan | Sarvaltan | Sarvan | Selectan | Tareg | Univaltan | V dio | V sar | V van | Valderid | Valmitan a | Valosartan | Valsabell | Valsan | Valsanin | Valsaone | Valsaor | Valsar | Valsarbell | Valsarect | Valsarotan | Valsartan bkw | Valsartel | Valsarvan | Valsatam | Valtaran | Valtrep | Vaotan | Varatan | Varban | Varetan | Vartan | Vasatan | Vzatan</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Anginet | Cinfaval | Diovan | Tabuvan</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Anginet | Arbiten | Diotens | Diovan | Reta | Tabuvan | Valpress | Valsartan arrow lab | Valustar | Valzap | Viostan</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Diovan | Suvartar | Valsacor | Valsartan actavis | Valsartan Ingen Pharma | Valsartan krka | Valsartan Ranbaxy | Valsartan sandoz | Valzap | Vanatex | Vapress</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Diovan | Valsartan EG | Valsartan mylan | Valsartan ratiopharm</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Diovan | Valsacor | Valsartan krka | Valzap | Vanatex | Vapress</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Atensil | Starval | Tareg | Valphi | Vartex | Zenovan</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Acavexal | Alphatempix | Avalraam | Diovalte | Diovan | Innaban | Menfhipress | Navoid | Novogaba | Panathra | Ragamat | Thorin | Travisfarox | Vactory | Vagsar | Valsartan novartis | Valsartan ultra | Valsauro | Vapispre | Versalver | Viecal | Vigisan | Vivendal</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Diovan | Valsartan sandoz | Valzaar | Vytan</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Acovan | Anginet | Carvals | Codiolad | Diovan | Dony valsartan | Lastavin | Nucard | Valdix | Valsar denk | Valsartil</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Diovan | Vagrecor | Valsartan actavis | Valsartan Erc | Valsartan jubilant | Valsartan krka | Valsartan mylan | Valsartan sandoz | Valsartan xiromed</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Diovan | Valsartan actavis | Valsartan krka | Valsartan mylan | Valsartan sandoz</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Angipec | Avan | Diovan | Presix | Pressix | Starval | Tensioval | Valsapress | Valsaprin | Valsartan calox | Valsarvitae | Valsiprel | Valtan | Valtens | Vapresan | Varside</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Diovan | Dizant | Dizantin | Doh valsartan | Ritemed valsartan | Tareg | Torval | Trivan | Valazyd | Valsar | Valsolo | Valvex | Welcard</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Angiotan | C val | Converge | Cova | Dilval | Diovan | Listan | Nobel | Nuval | Sevia | Tulurik | Valforge | Valgen | Valid | Valken | Valmax | Valovan | Valpharm | Vals | Valsan | Valseta | Valstar | Valtec | Valtec high | Valtn | Varlan | Velcard | Velker | Velvet | Walsartan</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Anartan | Apo valsartan | Avasart | Awalone | Axudan | Bespres | Diovan | Dipper mono | Ivisart | Nortivan | Nortivan neo | Tensart | Valorion | Valsacor | Valsargen | Valsartan 123ratio | Valsartan Arrow | Valsartan aurobindo | Valsartan Aurovitas | Valsartan genoptim | Valsartan medical valley | Valsartan orion | Valsartan Ranbaxy | Valsotens | Valtap | Valzek | Vanatex | Walsartan krka | Zelvartan</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Diovan</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Diovan | Molesart | Tareg | Valsartan actavis | Valsartan alter | Valsartan aurobindo | Valsartan baldacci | Valsartan Bluesar | Valsartan cinfa | Valsartan farmoz | Valsartan generis | Valsartan limeg | Valsartan mylan | Valsartan Pentafarma | Valsartan pharmacons | Valsartan pimentini | Valsartan ratiopharm | Valsartan sandoz | Valsartan stada | Valsartan tecnilor | Valsartan tetrafarma | Valsartan teva | Valsartan toLife | Valsartan zentiva</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Diovan | Europres | Valaplex | Valsartan bauel top | Vartalan</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Anginet | Arbiten | Diostar | Diovan | Tabuvan | Valzaar | Vanguard</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Avassan | Coreton | Diovan | Valsacor | Valsargamma | Valsartan teva | Valsartan torrent | Valsartan zentiva | Vapress</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Artinova | Diovan | Nortivan | Sartavel | Tantordio | Tareg | Valaar | Valsacor | Valsaforce | Valsartan akrikhin | Valsartan ms | Valsartan sz | Valsartan zentiva | Valz</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Anginet | Arbaval | Arbiten | Diostar | Diovan | Tabuvan | Valista | Valtense</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Diovan | Tanvacare | Valsartan 2care4 | Valsartan actavis | Valsartan ebb | Valsartan jubilant | Valsartan krka | Valsartan orion | Valsartan Ranbaxy | Valsartan sandoz | Valsartan teva | Valsartore | Valtsu</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Diovan | Starval | Valsartan sandoz</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Diovan | Valsacor | Valsartan pliva | Valsartan teva | Valsotens</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Diovan | Valsacor | Valsargamma | Valsartan +pharma | Valsartan actavis | Valsartan krka | Valzap | Vapress | Vasopentol</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Dioforge | Diovan | Tareg | Valatan | Valpres | Valsarin 160 | Valsarin 320</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Diostar | Reta | Tareg | Tazar | Tensiovals | Val | Valsartan Winthrop | Valsotens | Zarteg</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Cardopan | Diovan | Limiten | Premium | Tamgard | Valcor | Wansaar</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Daianxo | Diovan | Disartan | Ditan | Diyaval | Kovan | Prevan | Retonin | Tareg | Vaks | Valazyd | Valen | Valsardin | Valsart | Vosaa</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Adeniz | Diocor solo | Diocor solo 160 | Diocor solo 80 | Diosar | Diovan | Sacord | Tiara solo | Valmisar | Valsacor | Valsar | Valsartan jubilant | Valsartan krka | Valsartan sandoz | Valsartan zentiva | Vasar</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Anginet | Valazyd | Valsar</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Asortan | Diovan | Hipotensyl | Simultan | Valdix | Valopral | Valsacor | Valsartan athena | Valsartan Ion</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Acavexal | Alsart | Brasart | Brasartan | Cofasure | Diovan | Ofadivan | Valpresan | Valsacor | Valsan | Vartaz | Vasaten</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Doraval | Dovalic | Opevalsart | Rusartin | Valsacard | Valsarfast | Valsgim | Vasartim | Veesar</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Adco valsartan | Diolo | Diovan | Dynaval | Migroben | Regoval | Tareg | Valant | Valazyd | Valheft | Valsartan unicorn | Vasovan | Zomevek</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Diovan | Starval | Valzaar | Zomevek</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Diovan | Dynaval | Valsar | Vasar</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-30250510">
<a name="30250510"></a>Alhowary AA, Odat H, Alali O, Al-Omari A. Intraoperative angioedema induced by angiotensin II receptor blocker: a case report. <i>Patient Saf Surg</i>. 2018;12:27. doi:10.1186/s13037-018-0174-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/30250510/pubmed" id="30250510" target="_blank">30250510</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15669052">
<a name="15669052"></a>Alwan S, Polifka JE, Friedman JM. Angiotensin II Receptor Antagonist Treatment During Pregnancy. <i>Birth Defects Res A Clin Mol Teratol.</i> 2005;73(2):123-130. doi:10.1002/bdra.20102<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/15669052/pubmed" id="15669052" target="_blank">15669052</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>American Academy of Pediatrics Committee on Drugs. "Inactive" ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278. doi:10.1542/peds.99.2.268<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30575676">
<a name="30575676"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG practice bulletin no. 203: chronic hypertension in pregnancy. <i>Obstet Gynecol</i>. 2019;133(1):e26-e50. doi:10.1097/AOG.0000000000003020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/30575676/pubmed" id="30575676" target="_blank">30575676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADA.1">
<a name="ADA.1"></a>American Diabetes Association (ADA). Standards of medical care in diabetes–2021. <i>Diabetes Care</i>. 2021;44(suppl 1):S1-S232. Accessed January 12, 2021. https://care.diabetesjournals.org/content/44/Supplement_1.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25260718">
<a name="25260718"></a>Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>J Am Coll Cardiol</i>. 2014;64(24):2713-2714]. <i>J Am Coll Cardiol</i>. 2014;64(24):e139-e228. doi:10.1016/j.jacc.2014.09.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/25260718/pubmed" id="25260718" target="_blank">25260718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20585070">
<a name="20585070"></a>Antoniou T, Gomes T, Juurlink DN, Loutfy MR, Glazier RH, Mamdani MM. Trimethoprim-sulfamethoxazole-induced hyperkalemia in patients receiving inhibitors of the renin-angiotensin system: a population-based study. <i>Arch Intern Med</i>. 2010;170(12):1045-1049. doi:10.1001/archinternmed.2010.142<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/20585070/pubmed" id="20585070" target="_blank">20585070</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10724055">
<a name="10724055"></a>Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? <i>Arch Intern Med</i>. 2000;160(5):685-693. doi:10.1001/archinte.160.5.685<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/10724055/pubmed" id="10724055" target="_blank">10724055</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21970934">
<a name="21970934"></a>Beltrami L, Zanichelli A, Zingale L, Vacchini R, Carugo S, Cicardi M. Long-term follow-up of 111 patients with angiotensin-converting enzyme inhibitor-related angioedema. <i>J Hypertens</i>. 2011;29(11):2273-2277. doi:10.1097/HJH.0b013e32834b4b9b<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/21970934/pubmed" id="21970934" target="_blank">21970934</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15329835">
<a name="15329835"></a>Berkane N, Carlier P, Verstraete L, et al. Fetal Toxicity of Valsartan and Possible Reversible Adverse Side Effects. <i>Birth Defects Res A Clin Mol Teratol.</i> 2004;70(8):547-549. doi:10.1002/bdra.20047<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/15329835/pubmed" id="15329835" target="_blank">15329835</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33942342">
<a name="33942342"></a>Biggins SW, Angeli P, Garcia-Tsao G, et al. Diagnosis, evaluation, and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American Association for the Study of Liver Diseases. <i>Hepatology</i>. 2021;74(2):1014-1048. doi:10.1002/hep.31884<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/33942342/pubmed" id="33942342" target="_blank">33942342</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19179299">
<a name="19179299"></a>Blumer J, Batisky DL, Wells T, Shi V, Solar-Yohay S, Sunkara G. Pharmacokinetics of valsartan in pediatric and adolescent subjects with hypertension. <i>J Clin Pharmacol</i>. 2009;49(2):235-241. doi:10.1177/0091270008329547<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/19179299/pubmed" id="19179299" target="_blank">19179299</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15590878">
<a name="15590878"></a>Bos-Thompson MA, Hillaire-Buys D, Muller F, et al. Fetal Toxic Effects of Angiotensin II Receptor Antagonists: Case Report and Follow-Up After Birth. <i>Ann Pharmacother.</i> 2005;39(1):157-161. doi:10.1345/aph.1E250<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/15590878/pubmed" id="15590878" target="_blank">15590878</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23721258">
<a name="23721258"></a>Brewster LM, Seedat YK. Why do hypertensive patients of African ancestry respond better to calcium blockers and diuretics than to ACE inhibitors and β-adrenergic blockers? A systematic review. <i>BMC Med</i>. 2013;11:141. doi:10.1186/1741-7015-11-141<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/23721258/pubmed" id="23721258" target="_blank">23721258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CanadianDiabetesAssociation.2013">
<a name="CanadianDiabetesAssociation.2013"></a>Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2013 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. <i>Can J Diabetes. </i> 2013;35(suppl 1):1-212.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Cattran.1">
<a name="Cattran.1"></a>Cattran DC, Appel GB, Coppo R. IgA nephropathy: treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed December 13, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31841131">
<a name="31841131"></a>Cífková R, Johnson MR, Kahan T, et al. Peripartum management of hypertension: a position paper of the ESC Council on Hypertension and the European Society of Hypertension. <i>Eur Heart J Cardiovasc Pharmacother</i>. 2020;6(6):384-393. doi:10.1093/ehjcvp/pvz082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/31841131/pubmed" id="31841131" target="_blank">31841131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17996561">
<a name="17996561"></a>Desai AS, Swedberg K, McMurray JJ, et al; CHARM Program Investigators. Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program. <i>J Am Coll Cardiol</i>. 2007;50(20):1959-1966. doi:10.1016/j.jacc.2007.07.067<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/17996561/pubmed" id="17996561" target="_blank">17996561</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Diovan.1">
<a name="Diovan.1"></a>Diovan (valsartan) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; April 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Diovan.2">
<a name="Diovan.2"></a>Diovan (valsartan) [product monograph]. Montreal, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; March 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36481180">
<a name="36481180"></a>Fakhouri F, Schwotzer N, Cabiddu G, et al. Glomerular diseases in pregnancy: pragmatic recommendations for clinical management. <i>Kidney Int.</i> 2022:S0085-2538(22)01015-8. doi:10.1016/j.kint.2022.10.029<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/36481180/pubmed" id="36481180" target="_blank">36481180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25070666">
<a name="25070666"></a>Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACC/AHA/AATS/PCNA/SCAI/STS Focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. <i>Circulation.</i> 2014;130:1749-1767. doi:10.1161/CIR.0000000000000095.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/25070666/pubmed" id="25070666" target="_blank">25070666</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23166211">
<a name="23166211"></a>Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. <i>Circulation.</i> 2012;126(25):3097-3137. doi:10.1161/CIR.0b013e318277d6a0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/23166211/pubmed" id="23166211" target="_blank">23166211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25085962">
<a name="25085962"></a>Fleisher LA, Fleischmann KE, Auerbach AD, et al. 2014 ACC/AHA guideline on perioperative cardiovascular evaluation and management of patients undergoing noncardiac surgery: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;130(24):2215-2245. doi:10.1161/CIR.0000000000000105.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/25085962/pubmed" id="25085962" target="_blank">25085962</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30177515">
<a name="30177515"></a>Flynn JT, Kaelber DC, Baker-Smith CM, et al; Subcommittee on Screening and Management of High Blood Pressure in Children. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. <i>Pediatrics</i>. 2017;140(3):e20171904. doi:10.1542/peds.2018-1739<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/30177515/pubmed" id="30177515" target="_blank">30177515</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18591457">
<a name="18591457"></a>Flynn JT, Meyers KE, Neto JP, et al. Efficacy and safety of the Angiotensin receptor blocker valsartan in children with hypertension aged 1 to 5 years. <i>Hypertension</i>. 2008;52(2):222-228. doi:10.1161/HYPERTENSIONAHA.108.111054<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/18591457/pubmed" id="18591457" target="_blank">18591457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26934393">
<a name="26934393"></a>Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an Endocrine Society Clinical Practice Guideline. <i>J Clin Endocrinol Metab</i>. 2016;101(5):1889-1916. doi:10.1210/jc.2015-4061.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/26934393/pubmed" id="26934393" target="_blank">26934393</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34984237">
<a name="34984237"></a>Gao Z, Cao Y, Zeng X, Song X. Valsartan-associated bullous pemphigoid initially presenting as erythema multiforme. <i>Health Sci Rep</i>. 2021;4(4):e452. doi:10.1002/hsr2.452<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/34984237/pubmed" id="34984237" target="_blank">34984237</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19456765">
<a name="19456765"></a>Gencoglan G, Ceylan C, Kazandi AC. Linear lichenoid drug eruption induced by valsartan. <i>Clin Exp Dermatol</i>. 2009;34(7):e334-e335. doi:10.1111/j.1365-2230.2009.03283.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/19456765/pubmed" id="19456765" target="_blank">19456765</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Guyer.1">
<a name="Guyer.1"></a>Guyer AC, Banerji A. ACE inhibitor-induced angioedema. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. November 2, 2021. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35363499">
<a name="35363499"></a>Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i>. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/35363499/pubmed" id="35363499" target="_blank">35363499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29808707">
<a name="29808707"></a>Helmer A, Slater N, Smithgall S. A review of ACE inhibitors and ARBs in black patients with hypertension. <i>Ann Pharmacother</i>. 2018;52(11):1143-1151. doi:10.1177/1060028018779082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/29808707/pubmed" id="29808707" target="_blank">29808707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22064600">
<a name="22064600"></a>Hillis LD, Smith PK, Anderson JL, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <i>Circulation.</i> 2011;124(23):2610-2642. doi:10.1161/CIR.0b013e31823b5fee<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/22064600/pubmed" id="22064600" target="_blank">22064600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20838200">
<a name="20838200"></a>Kalra A, Cooley C, Palaniswamy C, Kalra A, Zanotti-Cavazzoni SL. Valsartan-induced angioedema in a patient on angiotensin-converting enzyme inhibitor for years: case report and literature review. <i>Am J Ther</i>. 2012;19(6):e189-e192. doi:10.1097/MJT.0b013e3181f28f84<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/20838200/pubmed" id="20838200" target="_blank">20838200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33637192">
<a name="33637192"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. <i>Kidney Int</i>. 2021b;99(3S):S1-S87. doi:10.1016/j.kint.2020.11.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/33637192/pubmed" id="33637192" target="_blank">33637192</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDIGO.2013">
<a name="KDIGO.2013"></a>Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. <i>Kidney Int Suppl.</i> 2013;3(1):1-150. https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf
                  </div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36272764">
<a name="36272764"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. <i>Kidney Int</i>. 2022;102(suppl 5):S1-S127. doi:10.1016/j.kint.2022.06.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/36272764/pubmed" id="36272764" target="_blank">36272764</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34556256">
<a name="34556256"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 clinical practice guideline for the management of glomerular diseases. <i>Kidney Int</i>. 2021a;100(suppl 4):S1-S276. doi:10.1016/j.kint.2021.05.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/34556256/pubmed" id="34556256" target="_blank">34556256</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25018935">
<a name="25018935"></a>KDIGO. Chapter 10: Immunoglobulin A nephropathy. <i>Kidney Int Suppl</i> (2011). 2012;2(2):209-217. doi:10.1038/kisup.2012.23<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/25018935/pubmed" id="25018935" target="_blank">25018935</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1855477">
<a name="1855477"></a>Kifor I, Moore TJ, Fallo F, et al. Potassium-stimulated angiotensin release from superfused adrenal capsules and enzymatically dispersed cells of the zona glomerulosa. <i>Endocrinology</i>. 1991;129(2):823-831. doi:10.1210/endo-129-2-823<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/1855477/pubmed" id="1855477" target="_blank">1855477</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23176216">
<a name="23176216"></a>Kobori H, Mori H, Masaki T, Nishiyama A. Angiotensin II blockade and renal protection. <i>Curr Pharm Des</i>. 2013;19(17):3033-3042. doi:10.2174/1381612811319170009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/23176216/pubmed" id="23176216" target="_blank">23176216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16632013">
<a name="16632013"></a>Li PK, Leung CB, et al; HKVIN Study Group. Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. <i>Am J Kidney Dis</i>. 2006;47(5):751-760. doi:10.1053/j.ajkd.2006.01.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/16632013/pubmed" id="16632013" target="_blank">16632013</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35577426">
<a name="35577426"></a>Magee LA, Smith GN, Bloch C, et al. Guideline no. 426: hypertensive disorders of pregnancy: diagnosis, prediction, prevention, and management. <i>J Obstet Gynaecol Can</i>. 2022;44(5):547-571.e1. doi:10.1016/j.jogc.2022.03.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/35577426/pubmed" id="35577426" target="_blank">35577426</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mann.2">
<a name="Mann.2"></a>Mann JFE, Bakris GL. Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed January 28, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Mann.1">
<a name="Mann.1"></a>Mann JFE, Flack JM. Choice of drug therapy in primary (essential) hypertension. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 7, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Meyer.2020">
<a name="Meyer.2020"></a>Meyer TE. Primary pharmacologic therapy of heart failure with reduced ejection fraction in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. Accessed November 2, 2021. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21974764">
<a name="21974764"></a>Meyers KE, Lieberman K, Solar-Yohay S, Han G, Shi V. The efficacy and safety of valsartan in obese and non-obese pediatric hypertensive patients. <i>J Clin Hypertens (Greenwich)</i>. 2011;13(10):758-766. doi:10.1111/j.1751-7176.2011.00502.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/21974764/pubmed" id="21974764" target="_blank">21974764</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.1">
<a name="NICE.1"></a>National Institute for Health and Care Excellence (NICE). NICE guideline hypertension in pregnancy: diagnosis and management. www.nice.org.uk/guidance/ng133. Published June 25, 2019. Accessed December 1, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24589852">
<a name="24589852"></a>Nishimura RA, Otto CM, Bonow RO, et al, 2014 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(23):2440-92. doi:10.1161/CIR.0000000000000029.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/24589852/pubmed" id="24589852" target="_blank">24589852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23247304">
<a name="23247304"></a>O'Gara PT, Kushner FG, Ascheim DD, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines [published correction appears in <i>Circulation</i>. 2013;128(25):e481]. <i>Circulation</i>. 2013;127(4):e362-e425. doi:10.1161/CIR.0b013e3182742cf6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/23247304/pubmed" id="23247304" target="_blank">23247304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22257082">
<a name="22257082"></a>Ozturk G, Turk BG, Senturk B, Turkmen M, Kandiloglu G. Exanthematous drug eruption due to valsartan. <i>Cutan Ocul Toxicol</i>. 2012;31(4):335-337. doi:10.3109/15569527.2011.647179<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/22257082/pubmed" id="22257082" target="_blank">22257082</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15295051">
<a name="15295051"></a>Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. <i>N Engl J Med</i>. 2004;351(6):585-592. doi:10.1056/NEJMra035279<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/15295051/pubmed" id="15295051" target="_blank">15295051</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24262001">
<a name="24262001"></a>Park IW, Sheen SS, Yoon D, et al. Onset time of hyperkalaemia after angiotensin receptor blocker initiation: when should we start serum potassium monitoring? <i>J Clin Pharm Ther</i>. 2014;39(1):61-68. doi:10.1111/jcpt.12109<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/24262001/pubmed" id="24262001" target="_blank">24262001</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Perkovic.1">
<a name="Perkovic.1"></a>Perkovic V. Treatment of diabetic kidney disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 2, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Prasad.1">
<a name="Prasad.1"></a>Prasad P, Mangat S, Choi L, et al. Effect of renal function on the pharmacokinetics of valsartan. <i>Clin Drug Invest</i>. 1997;13(4):207-214. doi:10.2165/00044011-199713040-00005</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21883995">
<a name="21883995"></a>Raebel MA. Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. <i>Cardiovasc Ther</i>. 2012;30(3):e156-e166. doi:10.1111/j.1755-5922.2010.00258.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/21883995/pubmed" id="21883995" target="_blank">21883995</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30618189">
<a name="30618189"></a>Rasmussen ER, Pottegård A, Bygum A, von Buchwald C, Homøe P, Hallas J. Angiotensin II receptor blockers are safe in patients with prior angioedema related to angiotensin-converting enzyme inhibitors - a nationwide registry-based cohort study. <i>J Intern Med</i>. 2019;285(5):553-561. doi:10.1111/joim.12867<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/30618189/pubmed" id="30618189" target="_blank">30618189</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to the manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30165544">
<a name="30165544"></a>Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J,et al; ESC Scientific Document Group. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. <i>Eur Heart J</i>. 2018;39(34):3165-3241. doi:10.1093/eurheartj/ehy340<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/30165544/pubmed" id="30165544" target="_blank">30165544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25840695">
<a name="25840695"></a>Rosendorff C, Lackland DT, Allison M, et al; American Heart Association, American College of Cardiology, and American Society of Hypertension. Treatment of hypertension in patients with coronary artery disease: A scientific statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. <i>J Am Soc Hypertens</i>. 2015;9(6):453-498. doi:10.1016/j.jash.2015.03.002.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/25840695/pubmed" id="25840695" target="_blank">25840695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23463403">
<a name="23463403"></a>Runyon BA; AASLD. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012. <i>Hepatology</i>. 2013;57(4):1651-1653. doi:10.1002/hep.2635<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/23463403/pubmed" id="23463403" target="_blank">23463403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18695383">
<a name="18695383"></a>Ryan MJ, Tuttle KR. Elevations in serum creatinine with RAAS blockade: why isn't it a sign of kidney injury? <i>Curr Opin Nephrol Hypertens</i>. 2008;17(5):443-449. doi:10.1097/MNH.0b013e32830a9606<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/18695383/pubmed" id="18695383" target="_blank">18695383</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23511339">
<a name="23511339"></a>Schaefer F, Coppo R, Bagga A, et al. Efficacy and safety of valsartan in hypertensive children 6 months to 5 years of age. <i>J Hypertens</i>. 2013;31(5):993-1000. doi:10.1097/HJH.0b013e32835f5721<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/23511339/pubmed" id="23511339" target="_blank">23511339</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22025233">
<a name="22025233"></a>Schaefer F, Litwin M, Zachwieja J, et al. Efficacy and safety of valsartan compared to enalapril in hypertensive children: a 12-week, randomized, double-blind, parallel-group study. <i>J Hypertens</i>. 2011;29(12):2484-2490. doi:10.1097/HJH.0b013e32834c625c<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/22025233/pubmed" id="22025233" target="_blank">22025233</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11602506">
<a name="11602506"></a>Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS; Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. <i>Circulation</i>. 2001;104(16):1985-1991. doi:10.1161/hc4101.096153<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/11602506/pubmed" id="11602506" target="_blank">11602506</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23147456">
<a name="23147456"></a>Toh S, Reichman ME, Houstoun M, et al. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system [published correction appears in <i>Arch Intern Med</i>. 2013;173(1):14]. <i>Arch Intern Med</i>. 2012;172(20):1582-1589. doi:10.1001/2013.jamainternmed.34<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/23147456/pubmed" id="23147456" target="_blank">23147456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lifsa.1">
<a name="Lifsa.1"></a>Valsartan oral solution [prescribing information]. New Brunswick, NJ: Lifsa Drugs LLC; April 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10619572">
<a name="10619572"></a>Weir MR. Are drugs that block the renin-angiotensin system effective and safe in patients with renal insufficiency? <i>Am J Hypertens</i>. 1999;12(12 Pt 3):195S-203S. doi:10.1016/s0895-7061(99)00104-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/10619572/pubmed" id="10619572" target="_blank">10619572</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29133356">
<a name="29133356"></a>Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines [published correction appears in <i>Hypertension</i>. 2018;71(6):e140-e144]. <i>Hypertension</i>. 2018;71(6):e13-e115. doi:10.1161/HYP.0000000000000065.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/29133356/pubmed" id="29133356" target="_blank">29133356</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219. doi:10.1111/j.1525-139X.2007.00280.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/valsartan-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 10036 Version 553.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
